The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

First quarter organic revenue growth of 15.3% was driven by broad-based demand across all segments, particularly High-Value Product (HVP) components.

HVP components grew 23% organically, fueled by significant GLP-1 demand and high-teens growth in non-GLP-1 biologics and biosimilars.

Operational excellence initiatives in Europe, including accelerated onboarding and knowledge transfer, successfully increased production throughput to meet demand outstripping supply.

The Biologics business delivered 26% organic growth, benefiting from high win rates on new launches and easing regulations for biosimilars.

Annex 1 regulatory compliance is driving a multi-year shift from standard products to HVP components, with the combination of Annex 1 and HVP conversion expected to contribute 200 basis points to 2026 growth.

West Vantage (Contract Manufacturing) is pivoting toward drug handling, which management describes as more profitable and less capital-intensive than legacy manufacturing.

Margin expansion of 350 basis points was primarily attributed to favorable product mix and price contributions, offsetting plant ramp-up costs.

Full-year organic revenue growth guidance increased to 7% to 9%, reflecting improved demand visibility for both GLP-1 and non-GLP-1 markets.

Adjusted EPS guidance raised to $8.40 to $8.75, assuming continued margin expansion from HVP mix shift in the second half of the year.

Management anticipates a $40 million revenue headwind in the second half of 2026 due to the planned exit of a legacy CGM contract.

The SmartDose transaction is expected to close mid-year, with organic growth rates adjusted to account for the $55 million in 2025 comparable revenue.

Rising oil and commodity prices are incorporated into the outlook, with a projected net impact of single-digit millions after mitigation efforts.

A new $1 billion share repurchase program was authorized, with $298 million already executed in the first quarter.

The new Dublin West Vantage site is fully operational, supporting high-volume injectable therapies for diabetes and obesity.

CEO Eric Green announced plans to retire, with a successor expected to be appointed in the second half of 2026.

Capital expenditure efficiency is a priority, with full-year spending maintained at $250 million to $275 million despite higher revenue targets.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Growth is driven by commercialized drugs rather than just new launches, with biologics and biosimilars showing strong momentum.

Management expects non-GLP-1 HVP components to grow low double digits for the full year, contributing over 5 points of total company growth.

While initially a European regulatory driver, customers are increasingly standardizing global portfolios to meet these sterility standards.

Management noted that the FDA is making similar observations regarding sterility, potentially accelerating upgrades in the U.S. market.

Qualifying a second manufacturing site for a customer typically takes 6 to 12 months.

Current growth is being supported by increasing throughput at existing sites through operational excellence rather than just new physical footprints.

The drug handling business within West Vantage is expected to have gross margins at least twice as high as the legacy business it replaces.

Incremental revenue from this segment is projected at $20 million for 2026 but is expected to triple at full ramp by 2027.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.